US 12,441,780 B2
CD80 and CD86 binding protein compositions and uses thereof
Yang Liu, Potomac, MD (US); Pan Zheng, Potomac, MD (US); Martin Devenport, Gaithersburg, MD (US); Wei Wu, Washington, DC (US); Xuexiang Du, Washington, DC (US); Mingyue Liu, Washington, DC (US); and Fei Tang, Washington, DC (US)
Assigned to OncoC4, Inc., Rockville, MD (US); and Children's National Medical Center, Washington, DC (US)
Filed by ONCOC4, INC., Rockville, MD (US); and CHILDREN'S NATIONAL MEDICAL CENTER, Washington, DC (US)
Filed on Feb. 22, 2022, as Appl. No. 17/677,814.
Application 17/677,814 is a continuation of application No. 16/333,888, granted, now 11,261,233, previously published as PCT/US2017/052264, filed on Sep. 19, 2017.
Claims priority of provisional application 62/396,667, filed on Sep. 19, 2016.
Prior Publication US 2022/0259286 A1, Aug. 18, 2022
Int. Cl. C07K 14/705 (2006.01); A61K 38/17 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); A61P 37/02 (2006.01); A61P 37/06 (2006.01); C07K 14/00 (2006.01); C07K 16/28 (2006.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01)
CPC C07K 14/70596 (2013.01) [A61K 39/39541 (2013.01); A61P 35/00 (2018.01); A61P 37/06 (2018.01); C07K 14/00 (2013.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); A61K 38/00 (2013.01); A61K 2039/507 (2013.01); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/76 (2013.01); C07K 2319/30 (2013.01)] 17 Claims
 
1. A method of treating adverse events associated with a cancer immunotherapy in a subject in need thereof, comprising administering to the subject a CTLA-4 protein, wherein the CTLA-4 protein comprises an extracellular domain of CTLA-4 comprising the sequence set forth in SEQ ID NO: 38, and wherein the cancer immunotherapy comprises Ipilimumab or Tremelimumab.